source
- AstraZeneca halts late-stage lung cancer trial of volrustomig after disappointing interim resultsAstraZeneca announced it is stopping a Phase 3 study of its bispecific antibody volrustomig in metastatic non-small cell lung cancer after an interim analysis showed the drug is unlikely to meet it…
- AstraZeneca halts late-stage lung cancer trial of volrustomig after disappointing interim resultsAstraZeneca said it is ending its Phase 3 eVOLVE-Lung02 trial that evaluated the bispecific antibody volrustomig combined with chemotherapy as a first-line option for metastatic non-small cell lung…